4mdq
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{STRUCTURE_4mdq| PDB=4mdq | SCENE= }} | ||
| - | ===Structure of a novel submicromolar MDM2 inhibitor=== | ||
| - | {{ABSTRACT_PUBMED_24207125}} | ||
| - | == | + | ==Structure of a novel submicromolar MDM2 inhibitor== |
| - | [[http://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN | + | <StructureSection load='4mdq' size='340' side='right'caption='[[4mdq]], [[Resolution|resolution]] 2.12Å' scene=''> |
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4mdq]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MDQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4MDQ FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.119Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=28W:3-[(1R)-2-(BENZYLAMINO)-1-{[(2S)-1-(HYDROXYAMINO)-4-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL]-6-CHLORO-N-HYDROXY-1H-INDOLE-2-CARBOXAMIDE'>28W</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4mdq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mdq OCA], [https://pdbe.org/4mdq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4mdq RCSB], [https://www.ebi.ac.uk/pdbsum/4mdq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4mdq ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [https://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN] Note=Seems to be amplified in certain tumors (including soft tissue sarcomas, osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and bladder carcinomas. Four of the splice variants show loss of p53 binding. | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/MDM2_HUMAN MDM2_HUMAN] E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as an ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and promotes it to proteasomal degradation.<ref>PMID:12821780</ref> <ref>PMID:15053880</ref> <ref>PMID:15195100</ref> <ref>PMID:16337594</ref> <ref>PMID:15632057</ref> <ref>PMID:17290220</ref> <ref>PMID:19098711</ref> <ref>PMID:19219073</ref> <ref>PMID:19965871</ref> <ref>PMID:20858735</ref> <ref>PMID:20173098</ref> | ||
| - | == | + | ==See Also== |
| - | [[ | + | *[[MDM2 3D structures|MDM2 3D structures]] |
| - | + | == References == | |
| - | + | <references/> | |
| - | + | __TOC__ | |
| - | + | </StructureSection> | |
| - | == | + | [[Category: Homo sapiens]] |
| - | + | [[Category: Large Structures]] | |
| - | [[Category: | + | [[Category: Bista M]] |
| - | [[Category: | + | [[Category: Holak TA]] |
| - | [[Category: | + | [[Category: Popowicz G]] |
| - | [[Category: | + | |
| - | [[Category: | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Structure of a novel submicromolar MDM2 inhibitor
| |||||||||||
